Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MIGUEL ANGEL ISLAS-OHLMAYER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1295917425
CMS profile
59223
Location
EDGEWOOD, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$24,227.38

21 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $21,955.00 6
Travel and Lodging $1,708.60 6
Food and Beverage $563.78 9

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $12,876.47 8
Syndax Pharmaceuticals, Inc. $7,286.69 8
E.R. Squibb & Sons, L.L.C. $2,012.50 1
Incyte Corporation $1,926.24 2
Rigel Pharmaceuticals, Inc. $125.48 2

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MIGUEL ANGEL ISLAS-OHLMAYER

NPI 1295917425 · CMS profile ID 59223

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

EDGEWOOD, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295917425?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MIGUEL ANGEL ISLAS-OHLMAYER, NPI 1295917425, CMS profile ID 59223. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295917425?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MIGUEL ANGEL ISLAS-OHLMAYER, NPI 1295917425, CMS profile ID 59223. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295917425?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MIGUEL ANGEL ISLAS-OHLMAYER, NPI 1295917425, CMS profile ID 59223, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1295917425?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

21 matching records · $24,227.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 21 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–21 of 21.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Rigel Pharmaceuticals, Inc. $31.0912/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247380226 CMS
Syndax Pharmaceuticals, Inc. $23.7612/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238991726 CMS
Rigel Pharmaceuticals, Inc. $94.3911/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247379737 CMS
Novartis Pharmaceuticals Corporation $962.5011/11/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1200334466 CMS
Syndax Pharmaceuticals, Inc. $54.7609/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238991714 CMS
Syndax Pharmaceuticals, Inc. $65.7109/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238991716 CMS
Syndax Pharmaceuticals, Inc. $15.0809/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238991718 CMS
Syndax Pharmaceuticals, Inc. $553.9009/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238991720 CMS
Syndax Pharmaceuticals, Inc. $192.6609/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238991722 CMS
Syndax Pharmaceuticals, Inc. $6,255.0009/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238991724 CMS
Syndax Pharmaceuticals, Inc. $125.8209/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238991712 CMS
Novartis Pharmaceuticals Corporation $93.8309/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200286386 CMS
Novartis Pharmaceuticals Corporation $8,600.0009/17/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1200286388 CMS
Novartis Pharmaceuticals Corporation $296.8809/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200286390 CMS
Novartis Pharmaceuticals Corporation $361.5409/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200286392 CMS
Novartis Pharmaceuticals Corporation $288.5409/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200334460 CMS
Novartis Pharmaceuticals Corporation $73.1809/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200334462 CMS
E.R. Squibb & Sons, L.L.C. $2,012.5008/26/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1184488413 CMS
Novartis Pharmaceuticals Corporation $2,200.0007/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1200286384 CMS
Incyte Corporation $1,925.0006/25/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1226005151 CMS
Incyte Corporation $1.2405/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226005283 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $14,766.15 80
PY2020 $9,564.87 23
PY2021 $13,658.96 17
PY2022 $10,243.37 22
PY2023 $23,259.49 27
PY2024 $7,439.87 6
PY2025 $24,227.38 21

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $395.50 1
PY2025 Principal investigator $58,459.40 2
PY2024 Recipient $1,306.60 1
PY2024 Principal investigator $113,571.67 2
PY2023 Recipient $168.05 1
PY2023 Principal investigator $315,531.55 45
PY2022 Principal investigator $368,128.77 124
PY2021 Principal investigator $257,202.74 115
PY2020 Principal investigator $150,989.86 62
PY2019 Recipient $7,317.30 2
PY2019 Principal investigator $200,492.20 48

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

115 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Seagen Inc. $589.00 12/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672073
Principal investigator 1 Seagen Inc. $150.00 12/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672075
Principal investigator 1 Seagen Inc. $718.00 12/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672079
Principal investigator 1 Seagen Inc. $150.00 12/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672247
Principal investigator 1 Seagen Inc. $150.00 12/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672249
Principal investigator 1 Seagen Inc. $589.00 12/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672251
Principal investigator 1 Seagen Inc. $619.00 11/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672045
Principal investigator 1 Seagen Inc. $150.00 11/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672051
Principal investigator 1 Incyte Corporation $1,125.00 10/29/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE, INC.
A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 No dispute reported 06/30/2026 831068535
Principal investigator 1 Incyte Corporation $1,125.00 10/29/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE, INC.
A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 No dispute reported 06/30/2026 831068541
Principal investigator 1 Celgene Corporation $404.00 10/15/2021 Non-covered Recipient Entity
Oncology Hematology Care, Inc
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma No dispute reported 06/30/2026 807114625
Principal investigator 1 Genentech, Inc. $2,338.00 10/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
POLARIX No dispute reported 06/30/2026 835983249
Principal investigator 1 Incyte Corporation $956.00 10/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE, INC.
A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 No dispute reported 06/30/2026 831068547
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,063.00 10/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
Study of Ibrutinib and Rituximab in Treatment Naive Follicular Lymphoma No dispute reported 06/30/2026 786499007
Principal investigator 1 Seagen Inc. $2,211.00 10/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672021
Principal investigator 1 Seagen Inc. $956.00 10/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression No dispute reported 06/30/2026 792672025
Principal investigator 1 Seagen Inc. $3,827.00 10/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672027
Principal investigator 1 Seagen Inc. $4,211.00 10/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672029
Principal investigator 1 Seagen Inc. $2,211.00 10/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672189
Principal investigator 1 Seagen Inc. $956.00 10/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 792672191
Principal investigator 1 Seagen Inc. $2,211.00 10/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672193
Principal investigator 1 Seagen Inc. $2,211.00 10/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672195
Principal investigator 1 Seagen Inc. $2,211.00 10/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672197
Principal investigator 1 Seagen Inc. $2,211.00 10/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672203
Principal investigator 1 Seagen Inc. $2,211.00 10/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672207
Principal investigator 1 Seagen Inc. $956.00 10/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672225
Principal investigator 1 Celgene Corporation $2,300.00 09/23/2021 Non-covered Recipient Entity
Oncology Hematology Care, Inc
A Phase 3, Double-blind, Randomized Study to Compa No dispute reported 06/30/2026 807118585
Principal investigator 1 MorphoSys AG $8,075.00 09/15/2021 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) No dispute reported 06/30/2026 854739885
Principal investigator 1 Seagen Inc. $1,227.00 09/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672173
Principal investigator 1 Seagen Inc. $300.00 09/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672175
Principal investigator 1 Seagen Inc. $718.00 09/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672183
Principal investigator 1 Seagen Inc. $150.00 09/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672185
Principal investigator 1 Seagen Inc. $300.00 09/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672265
Principal investigator 1 Seagen Inc. $1,227.00 09/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672273
Principal investigator 1 TG Therapeutics, Inc. $550.00 09/15/2021 Non-covered Recipient Entity
Oncology Hematology Care Clinical Trials
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 850455029
Principal investigator 1 TG Therapeutics, Inc. $550.00 09/15/2021 Non-covered Recipient Entity
Oncology Hematology Care Clinical Trials
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 850455081
Principal investigator 1 TG Therapeutics, Inc. $500.00 09/15/2021 Non-covered Recipient Entity
Oncology Hematology Care Clinical Trials
UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkins Lymphoma No dispute reported 06/30/2026 850455085
Principal investigator 1 TG Therapeutics, Inc. $500.00 09/15/2021 Non-covered Recipient Entity
Oncology Hematology Care Clinical Trials
UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkins Lymphoma No dispute reported 06/30/2026 850455087
Principal investigator 1 Incyte Corporation $1,125.00 09/10/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE, INC.
A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 No dispute reported 06/30/2026 831068465
Principal investigator 1 Incyte Corporation $1,125.00 09/10/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE, INC.
A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 No dispute reported 06/30/2026 831068471
Principal investigator 1 Incyte Corporation $1,125.00 09/10/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE, INC.
A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 No dispute reported 06/30/2026 831068477
Principal investigator 1 Incyte Corporation $1,125.00 09/10/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE, INC.
A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 No dispute reported 06/30/2026 831068481
Principal investigator 1 Incyte Corporation $1,125.00 09/10/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE, INC.
A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 No dispute reported 06/30/2026 831068489
Principal investigator 1 Incyte Corporation $1,125.00 09/10/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE, INC.
A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 No dispute reported 06/30/2026 831068493
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,250.00 09/01/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Study of Ibrutinib and Rituximab in Treatment Naive Follicular Lymphoma No dispute reported 06/30/2026 786499005
Principal investigator 1 TG Therapeutics, Inc. $1,259.50 09/01/2021 Non-covered Recipient Entity
Oncology Hematology Care Clinical Trials
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 850454965
Principal investigator 1 TG Therapeutics, Inc. $1,259.49 09/01/2021 Non-covered Recipient Entity
Oncology Hematology Care Clinical Trials
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 850454967
Principal investigator 1 TG Therapeutics, Inc. $2,852.88 09/01/2021 Non-covered Recipient Entity
Oncology Hematology Care Clinical Trials
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 850455025
Principal investigator 1 TG Therapeutics, Inc. $8,439.50 09/01/2021 Non-covered Recipient Entity
Oncology Hematology Care Clinical Trials
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 850455027
Principal investigator 1 TG Therapeutics, Inc. $1,259.50 09/01/2021 Non-covered Recipient Entity
Oncology Hematology Care Clinical Trials
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 850455073
Principal investigator 1 TG Therapeutics, Inc. $2,852.88 09/01/2021 Non-covered Recipient Entity
Oncology Hematology Care Clinical Trials
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 850455075
Principal investigator 1 TG Therapeutics, Inc. $1,259.49 09/01/2021 Non-covered Recipient Entity
Oncology Hematology Care Clinical Trials
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 850455077
Principal investigator 1 TG Therapeutics, Inc. $8,439.50 09/01/2021 Non-covered Recipient Entity
Oncology Hematology Care Clinical Trials
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 850455079
Principal investigator 1 Seagen Inc. $3,585.00 08/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672091
Principal investigator 1 Incyte Corporation $956.00 07/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE, INC.
A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 No dispute reported 06/30/2026 831068499
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,063.00 07/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
Study of Ibrutinib and Rituximab in Treatment Naive Follicular Lymphoma No dispute reported 06/30/2026 786499003
Principal investigator 1 Seagen Inc. $3,585.00 07/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672081
Principal investigator 1 Seagen Inc. $956.00 07/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 792672083
Principal investigator 1 Seagen Inc. $6,800.00 07/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression No dispute reported 06/30/2026 792672085
Principal investigator 1 Seagen Inc. $754.00 07/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672087
Principal investigator 1 Seagen Inc. $3,827.00 07/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672089
Principal investigator 1 Seagen Inc. $3,585.00 07/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672253
Principal investigator 1 Seagen Inc. $3,827.00 07/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672255
Principal investigator 1 Seagen Inc. $956.00 07/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672257
Principal investigator 1 Seagen Inc. $956.00 07/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression No dispute reported 06/30/2026 792672259
Principal investigator 1 Seagen Inc. $3,585.00 07/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672263
Principal investigator 1 Seagen Inc. $102.00 06/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671959
Principal investigator 1 Seagen Inc. $3,585.00 06/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671961
Principal investigator 1 Seagen Inc. $3,585.00 05/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671955
Principal investigator 1 Seagen Inc. $3,585.00 05/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672009
Principal investigator 1 Seagen Inc. $3,585.00 05/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672011
Principal investigator 1 Incyte Corporation $1,125.00 04/16/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE, INC.
A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 No dispute reported 06/30/2026 831068436
Principal investigator 1 Genentech, Inc. $2,338.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
POLARIX No dispute reported 06/30/2026 835983243
Principal investigator 1 Incyte Corporation $956.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE, INC.
A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 No dispute reported 06/30/2026 831068453
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,063.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
Study of Ibrutinib and Rituximab in Treatment Naive Follicular Lymphoma No dispute reported 06/30/2026 786499001
Principal investigator 1 Seagen Inc. $2,211.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671935
Principal investigator 1 Seagen Inc. $4,435.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671937
Principal investigator 1 Seagen Inc. $956.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 792671939
Principal investigator 1 Seagen Inc. $3,827.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671941
Principal investigator 1 Seagen Inc. $1,356.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671945
Principal investigator 1 Seagen Inc. $1,280.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671953
Principal investigator 1 Seagen Inc. $2,211.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671967
Principal investigator 1 Seagen Inc. $956.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression No dispute reported 06/30/2026 792671971
Principal investigator 1 Seagen Inc. $2,211.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671973
Principal investigator 1 Seagen Inc. $2,211.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671975
Principal investigator 1 Seagen Inc. $2,211.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671977
Principal investigator 1 Seagen Inc. $2,211.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671979
Principal investigator 1 Seagen Inc. $2,211.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671981
Principal investigator 1 Seagen Inc. $2,211.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671983
Principal investigator 1 Seagen Inc. $2,211.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671991
Principal investigator 1 Seagen Inc. $2,211.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671993
Principal investigator 1 Seagen Inc. $2,211.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671995
Principal investigator 1 Seagen Inc. $4,435.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671999
Principal investigator 1 Seagen Inc. $2,211.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672001
Principal investigator 1 Seagen Inc. $2,211.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672003
Principal investigator 1 Seagen Inc. $2,211.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672005
Principal investigator 1 Seagen Inc. $956.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672007
Principal investigator 1 Seagen Inc. $3,585.00 03/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671929
Principal investigator 1 Seagen Inc. $4,193.00 03/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671931
Principal investigator 1 Seagen Inc. $3,585.00 03/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671963
Principal investigator 1 Seagen Inc. $4,193.00 03/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671969
Principal investigator 1 Celgene Corporation $9,093.00 02/15/2021 Non-covered Recipient Entity
Ohc Mercy West
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma No dispute reported 06/30/2026 807114907
Principal investigator 1 Incyte Corporation $500.00 02/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE, INC.
A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 No dispute reported 06/30/2026 831068419
Principal investigator 1 Seagen Inc. $3,827.00 02/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671925
Principal investigator 1 Seagen Inc. $3,640.00 02/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792671927
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $19,275.00 02/04/2021 Non-covered Recipient Entity
Us Oncology Res Llc
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices No dispute reported 06/30/2026 819905043
Principal investigator 1 Seagen Inc. $615.00 01/25/2021 Covered Recipient Teaching Hospital
Jewish Hospital Of Cincinnati
A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas No dispute reported 06/30/2026 792666007
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,868.00 01/15/2021 Non-covered Recipient Entity
Ohc Mercy West
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in US Community Oncology Practices No dispute reported 06/30/2026 819898437
Principal investigator 1 Incyte Corporation $956.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE, INC.
A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 No dispute reported 06/30/2026 831068413
Principal investigator 1 MorphoSys AG $965.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL No dispute reported 06/30/2026 854739845
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,063.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
Study of Ibrutinib and Rituximab in Treatment Naive Follicular Lymphoma No dispute reported 06/30/2026 786498999
Principal investigator 1 Seagen Inc. $956.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672275
Principal investigator 1 Seagen Inc. $3,640.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 792672277
Principal investigator 1 Seagen Inc. $956.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 792672281
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,250.00 01/08/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Study of Ibrutinib and Rituximab in Treatment Naive Follicular Lymphoma No dispute reported 06/30/2026 786498997